Cirrhosis is a progressive chronic liver disease character ized by diffuse fibrosis, severe disruption of the intra hepatic venous flow, portal hypertension and liver failure. The course of cirrhosis is divided into two stages 1 (FIG. 1) .
(FIG. 1).
Compensated cirrhosis defines the period between the onset of cirrhosis and the first major complication. During this period, which is rela tively long in most patients (>10 years), symptoms are absent or minor, but liver lesions and portal pressure steadily progress. The term decompensated cirrhosis defines the period follow ing the development of ascites (that is, the accumu lation of large amounts of fluid within the peritoneal cavity), variceal haemorrhage and/or hepatic encephalo pathy [2] [3] [4] . This period is associated with shortterm survival (3-5 years) .
Concepts about cirrhosis are rapidly changing. First, cirrhosis is no longer considered to be an irreversible progressive disease. Indeed, decompensated cirrhosis may return to compensated cirrhosis or even to pre cirrhotic phases if the cause of the disease is removed 5 . Second, the list of organ or system dysfunctions in cirrho sis (hepatic, renal, brain and circulatory) has been expanded to include the immune system, intestines, heart, lungs, adrenal glands, muscles and thyroid glands.
Third, new mechanisms involved in the pathogenesis of cirrhotic complications, such as dysbiosis of the micro biota 6 and systemic inflammation 7 have been recognized. Last, it is increasingly evident that patients rarely die as a consequence of an endstage irreversible destruction of the liver. Rather, in most patients, the cause of death is an acute deterioration in their clinical condition pro moted by a precipitating event -a syndrome termed acuteonchronic liver failure (ACLF) 8 . More than 13 distinct definitions of ACLF have been proposed. These definitions are generally based on personal experience or consensus agreements [9] [10] [11] [12] [13] [14] [15] 
The Asian Pacific Association for the Study of the Liver (APASL) definition has received major attention 11, 12 (BOX 1). This definition is based on positive and negative criteria. The main positive criteria are: prior diagnosis of chronic liver disease (cirrhotic or non cirrhotic, exclud ing isolated steatosis); a precipitating event that has a direct effect on the liver; and acute hepatic insult that causes acute liver failure. The main negative criteria in the APASL definition are: no prior history of acute decom pensation in patients with cirrhosis (decompensated cirrhosis would represent the presence of endstage pro gressive liver disease); and no extrahepatic precipitating event, such as bacterial infection. The APASL definition was based on a consensus conference.
The APASL proposal did not reach wide diffusion in Europe and North America for several reasons. First, the most common form of ACLF in these areas occurs in patients with decompensated cirrhosis in a closed temporal relationship with bacterial infections or active alcoholism 8, 13 (FIG. 1) , and these patients are not included in the APASL definition. Second, the concept that decompen sated cirrhosis represents a terminal phase of the disease is not the experience of European centres. Third, extrahepatic organ failure is the most character istic differential feature between patients with ACLF and those with acute decompensation in European patients. Last, ACLF in patients with noncirrhotic chronic liver disease is exceptional in Europe and North America owing to the low prevalence of hepatitis A virus, hepatitis B virus (HBV) and hepatitis E virus infections.
For these reasons, in 2009, the European Association for the Study of the LiverChronic Liver Failure (EASLCLIF) Consortium started a prospective, multi centre European observational study in 1,343 patients who were hospitalized for acute decompensation of cirrhosis (the CANONIC study). This study aimed to define ACLF in cirrhosis, to assess the prevalence and clinical course of the syndrome and to improve the accu racy of the prognostic scores currently available 8, [16] [17] [18] [19] [20] through an evidencebased pragmatic approach. The analysis of this study lead to a new definition with three major characteristics
: acute decompensation of cirrhosis; the presence of organ failure (or failures, which can be either hepatic or extrahepatic); and a high probability of shortterm (28day) mortality. Following the publication of the main articles derived from the CANONIC study, the definition, grading of severity of ACLF and prognostic scores proposed are widely used in Europe, Asia and North America for the assessment and treatment of patients with decompensated cirrhosis [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] .
It has been suggested that differences between APASL and EASLCLIF Consortium definitions are logical consequences of the distinct epidemiology of liver diseases in the east and in the west 28, 33 . However, the differences are more likely to be related to the dis tinct objectives by which both definitions were designed. The ACLF definition by the APASL consensus group was designed to identify a condition that anticipates the development of extrahepatic or multiple organ failure and death 11, 12 . By contrast, the goal of the CANONIC study was to characterize a syndrome in which organ failure (or failures) and high shortterm mortality are central features 8 . Attempts to unify both definitions have not been successful 34 . Recent investigations from Asia have com pared the two definitions in a large series of patients with cirrhosis 23, 26, 35 . FIGURE 2 compares the results of the largest Asian series 35 with those in the CANONIC study 8 . A coincident diagnosis by the APASL and the EASLCLIF Consortium definitions was observed in only a minority of patients in both series, indicating that the two ACLF definitions selected different patient populations (FIG. 2a) . The EASLCLIF Consortium defin ition was significantly more accurate in predict ing prognosis than the APASL definition in both the eastern and the western populations (FIG. 2b ). Significant differences in mortality depending on the diagnostic criteria were also observed in two other cohorts of patients from China 23 and India 26 . This Primer on ACLF in cirrhosis uses the EASLCLIF Consortium defin ition. The reader is referred to a review by Sarin and Choudhury 36 for a discussion of ACLF that is based on the APASL criteria.
Epidemiology
Worldwide prevalence and mortality ACLF is a major worldwide medical problem, with prevalence rates in atrisk populations in the region of 20-35% (TABLE 1) . The worldwide reported mortal ity of ACLF according to the EASLCLIF Consortium definition ranges between 30% and 50% and correlates closely with the number of organ failures. In Europe, the average 28day mortality rate without liver trans plantation reported by the CANONIC study was 1.9% in patients with decompensated cirrhosis without ACLF and 32.8% in patients with ACLF (23% in patients with ACLF grade 1, 31% in patients with ACLF grade 2 and 74% in patients with ACLF grade 3; see BOX 2 for details) 8 .
In the United States, a study using the North American Consortium for the Study of End Stage Liver Disease (NACSELD) criteria (BOX 1) reported that the 30day mortality rate associated with infected decompensated cirrhosis without ACLF was 8% and this rate increased to 27% in patients with one, 49% in patients with two, 64% in patients with three and 77% in patients with four organ failures 13 . In addi tion, in Asia, no signifi cant reduction in mortality in patients with ACLF has been observed over the past two decades, with mortality in the nationwide sample approaching 50% 36 .
In China, the average 28day transplantfree mor tality reported by Li et al. 24 in patients with decompen sated cirrhosis due to chronic HBV infection was 2.6% in patients without ACLF and 44% in patients with ACLF. This study used the EASLCLIF Consortium definition of ACLF and found mortality rates of 23.6% in patients with ACLF grade 1, 40.8% in patients with ACLF grade 2 and 60.2% in patients with ACLF grade 3 (REF. 24 ). Zhang et al. 23 reported similar findings in Chinese patients with decompensated cirrhosis of different aetiologies. The 90day mortality rate in patients without ACLF was 2.1% and in patients with ACLF grade 1 was 39.9%, ACLF grade 2 was 54.1% and ACLF grade 3 was 84.7% (using the EASLCLIF Consortium definition) 23 .
Precipitating events
Precipitating events of ACLF vary according to geo graphical areas and can be classified as hepatic or extra hepatic depending on their site of origin 14, 34, [37] [38] [39] (FIG. 1) .
Reactivation of chronic HBV, acute hepatitis A virus or hepatitis E virus infection 38 , acute alcoholic hepati tis and acute bacterial infection are the most frequent precipitating events of ACLF in Asia 23 . In the west, the most common precipitating events are active alcohol ism and bacterial infections, although in a considerable proportion of patients there is no recognizable precipi tating event 8 . The potential role of druginduced liver injury (DILI) as a precipitating event in ACLF has been insufficiently explored in both the east and the west.
Organ failures
In the CANONIC study 8 , among the different organ and system failures in ACLF, the most frequently affected organs or systems were the kidneys (55.8% of patients), followed by the liver (43.6% of patients), coagulation (27.7% of patients), the brain (24.1% of patients), circula tion (16.8% of patients) and the lungs (9.2% of patients). At first glance, it might be surprising that not all patients with ACLF had liver failure, but there are two important issues that should be taken into account. First, the level Figure 1 | The clinical course of cirrhosis. Acute-on-chronic liver failure (ACLF) can develop at any stage from compensated to decompensated cirrhosis, and can involve hepatic or extrahepatic precipitating events. A considerable proportion of patients have no identifiable triggering event. In this figure, paracentesis means 'large volume paracentesis' (>5 litres). Acute decompensation of cirrhosis defines the acute development of clinically evident ascites, hepatic encephalopathy, gastrointestinal haemorrhage or any combination of these in patients with or without prior history of these complications. Although bacterial infections are not specific complications of cirrhosis, they are considered as such in patients with prior history of ascites, haemorrhage or encephalopathy because of their high prevalence and their association with abnormalities related to cirrhosis, including bacterial translocation and impaired leukocyte function [1] [2] [3] [4] [5] [6] [7] [8] . DILI, drug-induced liver injury; TIPS, transjugular intrahepatic portosystemic shunt. Figure is adapted from an image provided courtesy of Jordi Bozzo, Avinguda de la Generalitat, Barcelona, Spain.
of bilirubin used to define liver failure was very high (≥12 mg per dl) and most (if not all) patients without liver failure also had abnormal bilirubin values, which implies a variable degree of impairment of liver function in these patients. Second, it is important to note that the definition of ACLF goes beyond the classic concept of decompen sation of cirrhosis and includes the consequences of cirrhosis on the function of other organs 7 .
Mechanisms/pathophysiology ACLF during the course of cirrhosis As indicated, cirrhosis is a progressive disease that inevit ably leads to death unless the aetiological mechanism is suppressed by appropriate treatment or a liver trans plantation is performed. Indeed, there is good evidence that discontinuation of alcohol ingestion in alcoholic cirrhosis, antiviral treatment in chronic HBVrelated and hepatitis C virusrelated cirrhosis and immuno suppressive therapy in autoimmune cirrhosis may trans form decompensated cirrhosis to compensated cirrhosis or even to precirrhotic phases 5 . By contrast, if the aetio logical mechanisms persist in patients with compen sated cirrhosis, hepatic fibrosis increases progressively as a consequence of continuous liver cell necrosis and inflammation, giving rise to progressive distortion of the liver architecture, reduction in liver parenchyma cells, increase in the intrahepatic resistance to the portal venous flow, portal hypertension, liver insufficiency and acute decompensation of the disease (FIG. 1) .
The development of complications, mainly ascites and, less frequently, variceal haemorrhage or hepatic encephalopathy, marks the onset of decompensated cirrhosis. Decompensated cirrhosis is characterized by impairment in the function of the liver and extrahepatic organs and systems, including: the brain (disturbances affecting cognitive, psychiatric and motor functions ranging from subclinical alterations to severe stupor and coma); the kidneys (impairment in renal sodium and free water excretion, intrarenal haemo dynamics, renal perfu sion and glomerular filtration rate); circulation (splanch nic arterial vasodilation leading to reduction in systemic vascular resistances and high cardiac output); the lungs (impairment in the ventilation/ perfusion ratio leading to hypoxia and hypo capnia); the heart (impairment in chronotropic and left ventricular systolic and diastolic functions); coagulation (as a result of impairment in the hepatic synthesis of coagulant and anticoagulant factors and increased fibrinolysis); the adrenal glands (impaired ability to provide adequate cortisol release in response to stress); the intestines (reduced motility, bacterial overgrowth and increased permeability of the mucosal barrier leading to increased translocation of bacteria and/or bacterial products from the intestinal lumen to the systemic circulation); the immune system (systemic inflammation and impaired function of poly morphonuclear leuko cytes and monocytes); the thyroid glands (impaired hormonal secretion); and muscles ( sarcopaenia) (FIG. 1) .
ACLF may develop at any phase of the disease from compensated to early or late decompensated cirrhosis (FIG. 1) . Thus, it is not a terminal event of a long standing decompensated cirrhosis. As indicated above
, organ failure is defined by an intense impairment in the function of six specific organs or systems that are impor tant in determining prognosis (the liver, the kidneys and the brain and the coagulation, circulatory and respiratory systems) 8 . Organ failure is the feature that differentiates ACLF from decompensated cirrhosis without ACLF. By contrast, organ dysfunction, which defines a less severe impairment in the function of these (and other) organs and systems, is the differential feature of decompen sated cirrhosis versus compensated cirrhosis. For instance, according to the CANONIC study 8 , brain failure is defined by a hepatic encephalopathy grade 3 or grade 4 of the West Haven classification, whereas brain dysfunc tion is defined by a hepatic encephalopathy grade 1 or grade 2. Similarly, renal dysfunction is defined by a serum creatin ine level of 1.5-1.9 mg per dl, whereas renal failure is defined be a serum creatinine level of ≥2 mg per dl.
Inflammation in ACLF
ACLF is associated with features of systemic inflam mation. For example, white blood cell count and plasma levels of Creactive protein and proinflammatory cytokines and chemokines, such as IL6, IL1β and IL8, are higher in patients with ACLF than in patients with cirrhosis without ACLF 8, 22 . Moreover, among patients with ACLF, the higher the ACLF severity, as estimated by the number of organ failures, the higher the plasma pro inflammatory cytokine or chemokine levels (R.M. and the 11, 12 , acute-on-chronic liver failure (ACLF) is the result of an acute direct hepatic insult (hepatotropic viral infections, active alcohol consumption or drug-induced liver injury) that causes liver failure. Liver failure is defined as jaundice (a serum bilirubin level of ≥5 mg per dl) and coagulopathy (an international normalized ratio of ≥1.5 or prothrombin activity of <40%). This liver failure is complicated within 4 weeks by clinical ascites and/or encephalopathy in a patient with previously diagnosed or undiagnosed chronic liver disease (including cirrhosis). Both compensated cirrhosis and non-cirrhotic chronic liver disease (non-alcoholic fatty liver disease-related chronic hepatic injury or chronic hepatitis with fibrosis or fibrosis due to other reasons) qualify as chronic liver disease. Bacterial infections are not considered hepatic insults. Patients with cirrhosis and known prior decompensation (jaundice, encephalopathy or ascites) who develop acute deterioration of their clinical status that is either related or unrelated to precipitating events are considered to have acute decompensation but not ACLF. CANONIC trialists, unpublished observations). The excessive systemic production of proinflammatory cytokines and chemokines -or the 'cytokine storm' -by the patient's immune system might cause collateral tissue damage 40 , a process termed immuno pathology 41 . As such, a cytokine storm might also be a prominent contrib utor to the development of organ failures in patients with cirrhosis. Of note, in patients with ACLF, a subset of CD14 + monocytes show overexpression of the tyrosine protein kinase MER (encoded by MERTK), which results in the inhibition of the production of inflammatory cytokines by these cells 22 , suggesting that a form of compensatory immunosuppression develops in parallel to the systemic inflammatory response.
The EASL-CLIF Consortium definition
There are two categories of ACLF: those in which the inducer (or inducers) of inflammation (for exam ple, bacterial infection or excessive alcohol intake) are identified and those in which there is no clinically identi fiable trigger (or triggers) 8 . In this Primer, the latter category is called ' ACLF with no clinically identifiable trigger' . Inducers of inflammation are either exogen ous or endogenous 42 . Among exogenous inducers, we discuss only bacterial inducers because the others are beyond the scope of this Primer and have been described elsewhere 42 . Although much of the molecular detail of how inflammation triggers ACLF remains to be eluci dated, it is likely that the following general processes play a key part. 'Bacterial inducers of inflammation' and 'endogenous inducers of inflammation' are potential mechanisms of inflammation in ACLF.
Bacterial inducers of inflammation. Bacterial patho gens can induce inflammation through two distinct classes of molecules: pathogenassociated molecular patterns (PAMPs) [42] [43] [44] and virulence factors 42, 45 . PAMPs are recognized by the host via dedicated receptors called pattern recognition receptors (PRRs) and examples of PRRs for bacterial ligands are detailed in FIG. 3a [42] [43] [44] . The engagement of PRRs results in the stimulation of signal ling cascades that activate transcription factors 43 . PRR activated transcription factors can induce an array of genes that encode molecules involved in inflammation, including proinflammatory cytokines 43, 45, 46 (FIG. 3b) .
The second class of bacterial inducers of inflam mation includes a large number of virulence factors 42, 44 . Unlike PAMPs, most of these factors are generally not recognized by dedicated receptors but can be sensed by the effects of their activity (a process called functional feature recognition) 38, [46] [47] [48] .
Endogenous inducers of inflammation. Endogenous inducers are released by necrotic cells or produced by extracellular matrix (ECM) breakdown in an injured tissue (such as the diseased liver in the case of ACLF) 42, 43 and are called damageassociated molecular patterns (DAMPs) 49 . DAMPs can be recognized by certain recep tors of the host, with this recognition resulting in 'sterile' inflammation. For example, high mobility group box 1 protein (HMGB1) engages the advanced glycosylation end productspecific receptor (RAGE), which cooperates with Tolllike receptors (TLRs; a class of PRRs) to induce an inflammatory response 42, 43, 49 . Additional factors that might also be involved in ACLF include necrotic cells, which may release members of the IL1 family such as IL1α and IL33 that trigger inflammation through their respective myeloid differentiation primary response protein 88 (MYD88)coupled cognate receptors 50 .
Outcomes of the inflammatory response. The purpose of the inflammatory response to bacterial infection is to promote host resistance by reducing bacterial burden, whereas that of sterile inflammation is to promote tissue repair [51] [52] [53] [54] . However, when these two categories of inflammatory responses are excessive, they may induce tissue damage 52 . During bacterial infection, the acute phase of the inflammatory response can be excessive and can cause immunopathology. For example, effec tors of the immune response, such as recruited neutro phils and inflammatory monocytes, activated T helper 1 (T H 1) and T H 17 cells, and cytotoxic T cells, are known to be associated with a high risk of immuno pathology 44 . There are also some examples of DAMPinduced excessive inflammatory response causing major tissue damage. Mice deficient for receptorinteracting serine/ threonine kinase 1 (Ripk1) develop RIPK3-mixed line age kinase domainlike protein (MLKL)mediated necroptosis resulting in systemic inflammation, multiple organ injury and death within 3 days of birth 50 . In this model, IL33 (a DAMP) drives systemic inflammation and severity. Therefore, the initial tissue injury caused by necroptosis may result in further tissue damage. In the context of severe bacterial infection, cell necrosis can occur (as a feature of immunopathology) and can result in DAMP release. In this case, released DAMPs can per petuate or accentuate inflammation originally triggered by bacterial inducers (PAMPs and virulence factors) 51 .
ACLF with identified inducers of inflammation
The relative contribution of these inflammatory pro cesses to ACLF probably differs depending on the trigger, and considerable research is still needed to fully elucidate the aetiological pathways of this syndrome. Of all the recognized precipitating events in ACLF, the mechanisms underlying two -sepsis and severe alcoholic hepatitis -are the best characterized and detailed below.
Sepsis-induced ACLF.
Organ dysfunction caused by a dysfunctional host immune response to bacterial infec tion defines sepsisinduced ACLF. 30% of patients with cirrhosis and ACLF have bacterial sepsis as an identi fiable trigger of the syndrome 8 . However, ACLF can also predispose to bacterial infection; indeed, a proportion of patients with ACLF develop bacterial infection during the course of the syndrome 8 . Among bacterial infec tions, spontaneous bacterial peritonitis (SBP), sepsis and pneumo nia were more frequently associated with ACLF than other infections in the CANONIC study 8 . In patients with cirrhosis and ascites, viable intestinal bacteria can cross the intestinal barrier and migrate to the general circulation and colonize the ascitic fluid 55, 56 . During the first hours of bacterial infection, patients with cirrhosis have higher plasma levels of pro inflammatory cytokines than patients without cirrho sis. This finding suggests the existence of exces sive inflammation in cirrhosis 57, 58 . The mechanisms that underlie this excessive inflammatory response to bac terial infection are incompletely understood 59 . In fact, most of our knowledge is based on experiments investi gating the innate immune response to lipopolysacchar ide (LPS), a PAMP recognized by TLR4 (REFS 59-61) (FIG. 3) . The response to LPS has been studied in ex vivo studies carried out in freshly isolated monocytes or peripheral blood mononuclear cells (PBMCs) from patients with and without cirrhosis. LPSstimulated pro duction of proinflammatory cytokines and chemokines is higher in cells from patients with cirrho sis than in control cells [62] [63] [64] [65] [66] . The mechanisms of the LPSinduced cytokine storm associated with cirrhosis are poorly understood. Ex vivo experiments have shown that PBMCs or monocytes from patients with cirrhosis show defects in the following negativefeedback mech anisms of TLR4 signalling: the activation of the phospho inositide 3kinase (PI3K)-AKT pathway 61, 65 ; inhibition of glycogen synthase kinase 3 activity 66 ; and the induc tion of IL1 receptorassociated kinase M (IRAKM; also known as IRKA3) 62 and of the antiinflammatory cytokine IL10 (REFS 61, 65) . Nevertheless, several other crucial mechanisms known to down regulate the TLR mediated inflammatory response under noncirrhotic conditions (in particular, the induction of tumour necrosis factorαinduced protein 3 (A20; also known as TNFAIP3) ) have not yet been investigated in the context of cirrhosis.
Following in vivo LPS challenge, plasma tumour necrosis factor (TNF) levels are significantly higher in cirrhotic than in noncirrhotic animals [67] [68] [69] [70] [71] . Moreover, in this setting, animals with, but not without, cirrhosis develop hepatocyte apoptosis and necrosis 70 . In addi tion, compared with normal livers, in cirrhotic livers, LPS elicits prolonged endoplasmic reticulum stress and a subsequent unfolded protein response that is responsible for sustained phosphorylation of eukaryotic translation initiation factor 2 subunitα (eIF2α) 70 . eIF2α phosphoryl ation is known to attenuate the translation of most RNAs 72 . In this context, hepatocyte TNFmediated cell death might occur in cirrhotic livers because of the lack of translation of nuclear factorκB (NFκB)dependent survival mRNAs into proteins. In support of this hypoth esis, normal hepatocytes exposed to high levels of TNF are protected against cell death because of the induction of NFκBdependent pro survival proteins 73 . Together, these findings led to the theory that, in cirrhosis, LPS recognition might result in severe liver damage that is due not only to an excessive innate immune response but also to the impairment of mechanisms involved in hepatocyte endoplasmic reticulum homeostasis.
Future studies should investigate the inflammatory response and tissue damage induced by the recogni tion of PAMPs other than LPS. It should also be noted that the role of inducers of inflammation, other than PAMPs, such as virulence factors and DAMPs, have not yet been studied in the context of sepsisinduced ACLF.
Severe alcoholic hepatitis. Results of the CANONIC study 8 suggest that 20% of cases of ACLF are caused by severe alcoholic hepatitis. In alcoholic hepatitis, the liver shows features of cell death and inflammation 74, 75 . However, the underlying mechanisms that explain these features are still poorly understood 75 and most of the following mechanisms require confirmation.
Excessive alcohol consumption alters the gut micro biota and increases intestinal permeability 75 . In addition, chronic and excessive systemic inflammation causes damage to the intestinal barrier. These alter ations might favour the translocation of bacteria into the blood stream [76] [77] [78] (FIG. 4) . Regardless of whether these bacteria cause infection, they release PAMPs (such as LPS) that can reach the liver where they are recognized by TLRs expressed in resident macrophages (called Kupffer cells). This recognition stimulates the production of pro inflammatory CXC chemokines, such as IL8 (REF. 79 ), that attract and activate neutrophils 80 . Neutrophil infil tration is a hallmark of alcoholic hepatitis 75 . Hepatocyte necrosis, which has been documented in severe alcoholic hepatitis 81 , might result in the release of DAMPs that would be recognized by different receptors mediating an inflammatory response, as described above.
Mitochondrial DNA (mtDNA) is a type of DAMP, and mtDNA stress might also contribute to inflam mation in the context of alcoholic hepatitis. Acetalde hyde metabolism results in hepatocyte reactive oxygen species (ROS) production 68 . ROS production is also stimulated by TNF 65 . In the context of chronic alcohol consumption 82 or after LPS challenge 83 , ROS over production induces mtDNA stress. In a mouse model of moderate mtDNA stress, mtDNA was shown to escape to the cytosol where it engaged a cellintrinsic response involving the innate cytosolic DNA sensor cyclic GMP AMP synthase (cGAS) (FIG. 3a) . cGAS engagement with mtDNA, in turn, mediates type I interferon (IFN) production and subsequent autocrine and paracrine induction of IFN target genes 84 . Thus, a cellintrinsic response to mtDNA stress might become an inflamma tory response at the tissue level and thereby might contribute to liver failure. Recent results suggest that the inhibition of liver regeneration might be involved in liver failure associ ated with severe alcoholic hepatitis 85 . Although hepatic progenitor cells are activated in livers with severe alcoholic hepatitis, these cells are committed to differ entiate into cholangiocytes (epithelial cells lining the bile duct) instead of hepatocytes 85 . Thus, it is possible that no replacement of hepatocytes that die as a result of alcoholic hepatitis occurs. Together, these find ings suggest that severe alcoholic hepatitis might be caused by both immunopathology and impaired hepatocyte regeneration.
ACLF with no identifiable trigger
The trigger of ACLF is unknown in approximately 40% of cases 8 . Although these patients show features of systemic inflammation 8 , one cannot clearly explain how the systemic inflammation is stimulated. Three hypotheses might explain the mechanisms that under lie inflammation in ACLF with no clinically identifiable trigger.
The first hypothesis is based on the existence of dys biosis of the gut microbiota in patients with cirrhosis (FIG. 4) . Dysbiosis associated with cirrhosis is typically characterized by a decrease in diversity, a decrease in Lachnospiraceae, Ruminococcaceae, Bacteroidaceae and Family XIV incertae sedis at the family level and a decrease in Bacteroides spp. at the genus level 6, [86] [87] [88] [89] . In addition, dysbiosis associated with cirrhosis involves an increase in Gramnegative Entero bacteriaceae, Fuso bacteriaceae and Porphyro monadaceae and in Grampositive Strepto coccaceae at the family level 6, [86] [87] [88] [89] . Decompensation of cirrhosis results in additional distinct compositional changes of the microbiota compared with compensated stages of liver disease 87 . There is a robust positive correlation between the abundance of certain bacterial family members and plasma levels of inflam matory cytokines (including IL6 and TNF in patients with ACLF) 90 . These findings suggest that metabolites produced by gut microbiota might contribute to systemic inflammation (FIG. 4) .
The second hypothesis is that some patients might have intestinal translocation of PAMPs, such as LPS or bacterial CpG DNA 91 (FIG. 3a) . These ligands might reach the liver and systemic circulation and then be recognized by TLRs. Thus, TLR recognition is generally not depend ent on microbial viability or invasiveness. During the peak phase of ACLF, systemic levels of LPS are higher than before the onset of ACLF and during remission of survivors 87, 91 , suggesting that higher systemic LPS levels correlate with disease severity. Interestingly, small intestinal bacterial overgrowth is a risk factor for increased systemic LPS levels in patients with cirrho sis 92 . Increased systemic levels of CpG DNA are found in patients with decompensated cirrhosis and without overt bacterial infection, and correlate with mortality 93 , suggesting that increased levels of CpG DNA might be involved in the development of ACLF in patients with acutely decompensated cirrhosis.
The third mechanism explaining inflammation in ACLF with no clinically identifiable trigger might be the release of DAMPs, for example, by necrotic hepato cytes. In patients and animals with acute liver failure, various DAMPs, such as HMGB1, that might contrib ute to inflammation are released 83 , but nothing is known about DAMPs in patients with ACLF.
Finally, another possible explanation for a failure to identify a precipitating event in ACLF could relate to a failure of current diagnostic tests or the testing protocol to identify infection or DILI.
Diagnosis, screening and prevention Defining organ failure and ACLF Diagnostic criteria of organ failure. One of the assump tions made to define the EASLCLIF criteria is that extra hepatic organ failure (or failures) is a major differential feature of ACLF. The CLIFSequential Organ Failure Assessment (CLIFSOFA) score was the original scale used to define organ failure in the CANONIC study 8 . It was derived from the SOFA score, a scale widely used in intensive care [16] [17] [18] [19] , which was then adapted to patients with chronic liver disease on the basis of published stud ies. Cutoff values were established after assessing the risk increase of 28day mortality rates in each of the last four CLIFSOFA score categories compared with that of the previous one in the patients enrolled in the CANONIC study. A simplified version of the CLIFSOFA score, the CLIF Consortium Organ Failure (CLIFC OF) score (TABLE 2) [43] [44] [45] [46] [47] [48] 167 . b | An example of PRR-mediated inflammation is the activation of inflammatory signalling pathways by extracellular and intracellular lipopolysaccharide (LPS). Detection of extracellular LPS by TLR4 engages two intracellular signalling conduits: the myeloid differentiation primary response protein 88 (MYD88) pathway (grey), involving the adaptor Toll-IL-1 receptor (TIR) domain-containing adaptor protein (TIRAP); and the TIR domain-containing adaptor protein-inducing IFNβ (TRIF) pathway (light green), involving the adaptor TIR domain-containing adaptor molecule 2 (TICAM2) 43 . The MYD88 pathway via tumour necrosis factor (TNF) receptor-associated factor 6 (TRAF6) stimulates different kinases (dark green), including inhibitor of nuclear factor-κB kinase (IKK) and mitogen-activated protein kinases (MAPKs), that activate master transcription factors (orange), NF-κB and activator protein 1 (AP-1), respectively. The MYD88 pathway also activates the transcription factor IFN regulatory factor 5 (IRF5). These activated transcription factors contribute to the induction of inflammatory genes (red), such as pro-inflammatory genes including TNF and IL6 and anti-inflammatory genes such as IL10 and IL1RN. The TRIF pathway involves TRAF3 activation of the transcription factor IRF3, which then contributes with other transcription factors to the induction of type I IFNs
43
. Intracellular LPS is recognized by the inflammatory caspases (caspase 4 and caspase 5 in humans and caspase 11 in mice) that stimulate the non-canonical NOD-, LRR-and pyrin domain-containing 3 (NLRP3) inflammasome 167, 168 . This results in the activation of caspase 1 (not shown), which promotes cleavage of IL-1β and IL-18 (REFS 167, 168) . Activation of caspase 4 and caspase 5 by intracellular LPS can trigger a programmed cell death called pyroptosis 169 . dsDNA, double-stranded DNA; NAIP5, neuronal apoptosis inhibitory protein 5; ssRNA, single-stranded RNA.
Mortality criteria. Another predefined criterion for the diagnosis of ACLF in the development of the EASLCLIF criteria was an expected 28day mortality rate of ≥15%. In the CANONIC series 8 , this criterion was present in patients with two or more organ failures, but not in patients with one organ failure (a 28day mortality rate of 14.6%). Additional risk factors were used to further categorize patients in this lowrisk subgroup. This analy sis produced subgroups of patients that fulfilled the three predefined criteria for ACLF (FIG. 5) : patients with two or more organ failures; patients with one organ failure (specifically kidney failure); and patients with nonrenal single organ failure if these failures are associated with renal and/or brain dysfunction.
Grades of severity of ACLF
Patients with decompensated cirrhosis can be strati fied into four groups of severity -no ACLF or ACLF grades 1-3 -on the basis of the type and the number of organ failures they have
. Kidney failure is the most prevalent organ failure in ACLF grade 1. For ACLF grade 2, liver failure is the most prevalent organ failure followed by kidney, brain and coagulation failure. For ACLF grade 3, the prevalence of all organ failures is high.
In the CANONIC study 8 , 23% of patients admitted to hospital had ACLF at admission. Furthermore, 11% of patients with no ACLF at admission developed the syndrome during hospitalization, which gives a total prevalence of ACLF of 31%. Among patients with ACLF, 51% had ACLF grade 1, 35% had ACLF grade 2 and 13% had ACLF grade 3. Besides providing the diag nosis of the syndrome, these criteria also provide data for rapid prognostic information, with the ACLF grade associated with different rates of mortality (TABLE 3) . The usefulness of these classification criteria as well as that of CLIFSOFA and CLIFC OF scores in assessing prognosis have been validated in independent series of patients 26, [29] [30] [31] 94, 95 .
Natural history of ACLF
ACLF is a syndrome that has potential for reversibil ity 96 . However, data from the CANONIC study clearly show that, despite this feature, mortality of patients with ACLF increases cumulatively even after these patients are discharged from the hospital. Specifically, mortality increases from approximately 20% at 28 days to >35% at 90 days in patients with ACLF grade 1 and from 30% to approximately 50% at 90 days in patients with ACLF grade 2 (REF. 8 ). Although there is consider able variability between patients 20, 21 , some broad principles regarding the course of the condition can be put forward. In general, at days 3-7 from presentation, approximately 50% patients with ACLF grade 1 will improve to having no ACLF, with a consequent 28day mortality rate of approximately 7%. In addition, 25% of patients with ACLF grade 1 will remain unchanged (that is, their ACLF grade will not change) with a 28day mortality rate of 24%. By con trast, approximately 25% of patients with ACLF grade 1 progress to ACLF grade 2 or ACLF grade 3; their 28day mortality rate is 53% and 88%, respectively. In patients presenting with ACLF grade 2, only 35% improve to having no ACLF or ACLF grade 1 at days 3-7 post presentation. Those patients who do improve have low 28day mortality rates of approximately 5%. In addi tion, approximately 50% of patients with ACLF grade 2 deterior ate to ACLF grade 3 (a 28day mortality rate of 90%) or remain the same (a 28day mortality rate of 26%). In patients presenting with ACLF grade 3, mortal ity rates remain very high with only approximately 13% improving to no ACLF or ACLF grade 1. The factors that were independently related to progression to more advanced grades were the CLIFC ACLF score (dis cussed below) and the presence of liver failure. These data indicate that the syndrome is indeed very dynamic and that early intervention is crucial to minimize the risk of death.
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Healthy gut microbiota
Intestinal epithelium Cirrhosis is associated with quantitative differences (bacterial overgrowth) and compositional changes of the gut microbiota, so called dysbiosis. Several factors might contribute to dysbiosis of the gut microbiota during cirrhosis including diet, use of antibiotics, decreased bile flow and intestinal motility, changes in gastric pH and impaired mucosal immunity. A second important feature of patients with cirrhosis is the translocation of bacteria. Disruption of tight junctions allows pathogen-associated molecular patterns (PAMPs) and possibly other microbial metabolites to use the paracellular route between adjacent intestinal epithelial cells for translocation. Intestinal permeability is already increased in precirrhotic stages, whereas translocation of viable bacteria is a characteristic of cirrhosis, particularly during decompensation. Bacteria probably use the transcellular route (transcytosis) through epithelial cells. PAMPs might also activate immune cells, including monocytes, macrophages and T cells, in the lamina propria of the intestines, leading to secretion of inflammatory mediators. Cytokines, such as tumour necrosis factor (TNF), IL-6, IL-17, nitric oxide (NO) and interferon-γ (IFNγ), are increased in the intestines of patients or animal models with cirrhosis [76] [77] [78] . Several of these mediators are known to contribute to a dysfunction of tight junctions. Conversely, the intestinal immune surveillance response might be impaired to remove translocated bacteria in the lamina propria.
Clinical risk factors
There is evidence that the clinical course of ACLF outlined above is true for all aetiologies of ACLF. In a retrospective study from China in patients who predomi nantly had HBVrelated cirrhosis, shortterm outcomes, which were the most closely associated with ACLF, were not affected by the nature of the precipitating illness 97 . Patients with hepatic precipitants, such as reactivation of HBV, had a shortterm (28day and 90day) mortality similar to patients with an extra hepatic precipitant, such as infection. This pattern was also observed in a second Chinese study 24 in patients with cirrhosis due to chronic HBV infection who developed ACLF. The 28day and 90day mortality rates for any given grade of ACLF in this study 24 were similar to those reported by the CANONIC study 8 and were unrelated to the presence and type of precipitating events (TABLE 4) . These studies, therefore, suggest that it is the number of organ failures and not the aetiology of cirrhosis or precipitating events that is the main risk factor of mortality.
A previous history of episodes of acute decompen sation was absent in 23% of patients with ACLF in the CANONIC study, indicating that the development of ACLF as the initial manifestation of decompensated cirrhosis is a relatively common feature. These patients without prior history of decompensation were younger, morefrequently alcoholics, had moresevere systemic inflammation and ACLF grade, and had higher short term mortality (42% versus 30%) than patients with ACLF with prior history of acute decompensation.
Prediction of prognosis
As ACLF is a dynamic syndrome, prognostic scores need to be dynamic so that they can be updated sequen tially on a daily basis, which would allow assessment of response to intervention, escalation for the need for urgent liver transplantation and determination of futility of ongoing treatment. The CANONIC study indicates that followup data within the first 3-7 days following diagnosis of ACLF are extremely important to predict clinical course since resolution; improvement or worsen ing of ACLF following standard medical therapy occur within this early time period in most patients 96 .
A prognostic model was developed and validated for patients with ACLF, referred to as the CLIFC ACLF score, and for patients with acute decompensation who did not fulfil criteria for the diagnosis of ACLF, which is called the CLIFC Acute Decompensation (CLIFC AD; www.clifconsortium.com) score. These two scores were designed because a single score was insufficient to satis factorily delineate the prognosis associated with acute decompensation and ACLF 8 . The CLIFC ACLF score comprises the CLIFC OF score, age and white blood cell count 20, 98 . The score is a number from 0 to 100; the higher the number, the greater the risk of death. The score was validated using prospectively collected data from a series of patients not included in the CANONIC study. The CLIFC ACLF score provided a significantly better estimate of the risk of death at 28 days, 90 days, 6 months and 12 months post presentation compared with the Model for EndStage Liver Disease (MELD) score, the MELDSodium score and the ChildPugh score 24, 32, 95, [99] [100] [101] . Compared with the CLIFC ACLF score, the MELD score underestimated the risk of death of patients by 20-30%, implying that organ alloca tion for transplantations using the MELD score seriously disadvantages the patient with ACLF 20 . The performance of the CLIFC ACLF score improved over the period of followup, suggesting that it should be updated daily 20 . The CLIFC AD score was developed in patients with acute decompensation without ACLF 98 . Variables that were found to be independently associated with survival were age, serum sodium level, serum creatin ine level, white blood cell count and international normal ized ratio. These generated a score between 0 and 100, which was also significantly more accurate in predict ing prognosis than the MELD, MELDSodium and ChildPugh scores 24, 98 . Patients with a CLIFC AD score Patients submitted to mechanical ventilation due to HE and not to a respiratory failure were considered as presenting a brain failure (cerebral subscore = 3). § Other patients enrolled in the study with mechanical ventilation were considered as presenting a respiratory failure (respiratory subscore = 3). Adapted with permission from REF. 20 , Elsevier.
of <45 had a 28day mortality rate of <3% and this category might identify a group of patients who could be discharged early from the hospital. Conversely, patients with a CLIFC AD score of >60 were at high risk of pro gression to fullblown ACLF and had a 28day mortality rate of approximately 20%, indicating that this is prob ably a 'preACLF' group. The CLIFC AD score was also validated for sequential use.
Prevention
Early diagnosis and treatment of potential precipitat ing events are essential in the prevention of ACLF, and several preventive measures have been shown to be effective 5, 55, [102] [103] [104] [105] . These all involve treating infections before they can go on to trigger ACLF and include: prompt administration of antibiotics tailored to the local epidemio logical pattern of resistance in patients with sus pected infections; longterm suppression of HBV infec tion or sustained eradication of hepatitis C virus infection in patients with compensated or decompensated cirrho sis; and intravenous administration of albumin at infec tion diagnosis in patients with SBP. In patients with SBP, albumin is highly effective in preventing the development of type 1 hepatorenal syndrome (HRS), which is a special form of ACLF characterized by rapidly progressive renal failure. This effect is probably as a consequence of plasma volume expansion and the modulatory effect of albumin on the systemic inflammation associated with PAMPs (such as LPS) 104, 105 . There is no evidence that intravenous albumin is effective in other bacterial infections 106, 107 . There is also indirect evidence in support of other potential preventive measures for ACLF. For example, longterm oral norfloxacin administration reduces the rate of SBP (and of other bacterial infections) and type 1 HRS in patients with decompensated cirrhosis 55,102,108-110 .
Norfloxacin acts by selectively reducing the Gram negative microbiota, decreasing the perme ability of the gut barrier via stimulation of IL10 release and modulat ing the immune response to bacterial trans location [111] [112] [113] . In addition, treatment of patients with severe acute alcoholic hepatitis with pentoxifylline, an inhibitor of macro phage production of TNF, or with the combin ation of prednisolone and intravenous Nacetylcysteine has been shown to reduce the incidence of type 1 HRS in some studies 114, 115 , presumably by modulating hepatic inflammation, but this has not been confirmed in a recent investigation 116 . Finally, shortterm administration of the combination of granulocyte colony stimulating factor (GCSF) plus darbepoetin (a synthetic analogue of erythro poietin) has been shown to improve liver function, to reduce the incidence of severe sepsis and to increase 1year survival in comparison to placebo in patients with decompensated cirrhosis 117 .
Management
Medical management
Medical management of ACLF consists of early recogni tion, treatment of the precipitating event and supportive care 8, 14, 118, 119 . Early treatment of the trigger is proven to reduce mortality, for example, in treatment of reactivated HBV infection with tenofovir or alcoholic hepatitis with steroids 75, 117, [119] [120] [121] . However, most of ACLF management is focused on supportive care 118 . Antibacterial therapy. As discussed above, bacterial infections are the precipitating event of ACLF in approx imately 35% of patients 14 (TABLE 4) . As such, there should be a low threshold for early initiation of antibiotics in patients with cirrhosis who have a bacterial infection. In patients with septic shock, every hour delay beyond presentation is associated with an adjusted odds ratio of overall death of 1.1 (REFS 122, 123) . Broad spectrum anti biotics should be used, particularly in patients with noso comial or health careassociated infections or in those with septic shock, as inappropriate initial anti microbial therapy increases the adjusted odds ratio of death by tenfold 122, 123 . Equally important to early initiation of anti biotics is prompt deescalation of antibiotics once an organism is identified and/or the patient shows clinical improvement. If no organism is identified and there is persistent clinical deterioration in the setting of broad spectrum antibiotics, antifungals should be considered 123 . Measures to prevent super infections (secondary infec tions that occur on top of a primary infection) should be implemented in patients with ACLF, including bundles of prevention and control of ventilatorassociated pneumo nia, catheterrelated bac teraemia and urinary tract infec tions, hand hygiene, barrier precautions and avoiding unnecessary instrumentation 124 . Infected and noninfected patients admitted with ACLF are highly predisposed to developing new bac terial infections during hospitalization (R.M. and the CANONIC trialists, unpublished observations). These infections act as a 'second hit' of the syndrome. Thus, pre vention, early diagnosis and treatment of these secondary infections are major issues in ACLF. HBV-specific therapy. Reactivation of HBV is a frequent precipitating event of ACLF in patients with cirrhosis in Asia. Antiviral treatment in patients with hepati tis Brelated ACLF improves liver function and increases shortterm and longterm survival [119] [120] [121] 125, 126 . Thus, early treatment with antiviral agents (such as lamivudine, teno fovir, entecavir or telbuvidine) should be started as soon as possible 121, 127 .
Immunomodulation. Patients with ACLF might bene fit from treatments that aim to restore immune func tion, such as albumin, Nacetylcysteine and GCSF 117, 128 . Indeed, results from a recent randomized controlled trial suggest that the administration of GCSF prevents the development of sepsis and improves shortterm survival in patients without severe forms of ACLF, who did not have sepsis, brain failure or multiple organ failure 128 . GCSF is thought to act by mobilizing stem cells from the bone marrow to the periphery, including the liver, thus improving liver regeneration.
Renal dysfunction and failure. Acute kidney injury (AKI) is the most frequent organ failure in ACLF 8, 129 . Common causes of AKI include prerenal, intrinsic causes and HRS 129 . Management of AKI differs depend ing on the underlying aetiology, and urinary biomarkers are helpful in identifying the cause of AKI 129, 130 . Volume resuscitation with crystalloids and/or albumin should be used in patients with prerenal AKI (that is, impairment in renal function related to hypovolaemia caused by excessive diuretic treatment). Terlipressin or noradrena line are the firstchoice treatment for HRS combined with volume expansion with albumin 129 . Terlipressin or noradrenaline are given to reduce the splanchnic arterial vasodilation causing systemic circulatory dysfunction and renal vasoconstriction in HRS. The effect of albumin was initially thought to be due to plasma volume expan sion. However, a potential effect of albumin in modulat ing the systemic inflammation of patients with ACLF has recently been proposed 7, 105 . Renal replacement therapy is used as a bridge to liver transplantation or liver-kidney transplantation in patients with severe AKI, although the dose and timing of dialysis has not been fully studied 129 . Cardiovascular failure. As in the management of sep sis, aggressive volume resuscitation and the initiation of vasoconstrictor agents (that is, noradrenaline) to main tain an adequate blood pressure for organ perfusion is crucial to counter the vasodilatory state that occurs with ACLF 14, 131 . The goal mean arterial pressure is >60 mmHg and careful attention should be made to volume admin istration with crystalloids given the predisposition of volume overload in patients with cirrhosis 118 . Colloids, including albumin, may also trigger volume overload. Terlipressin or vasopressin can be used as an adjunc tive agent. There is also growing evidence that adrenal insufficiency in ACLF can further compromise haemo dynamics 132 . Although still controversial, evaluation for adrenal insufficiency can be done by measuring random cortisol levels in the morning. If these levels are indeter minate, adrenal insufficiency can be confirmed with an adrenocorticotropic hormone (ACTH) test (also called the cosyntropin, tetracosactide or Synacthen test), which estimates the response of the adrenal glands to stress.
Brain dysfunction and failure. Treatment of encephalo pathy with tap water enemas, lactulose and oral non absorbable antibiotics (such as rifaximin and neomycin), by improving the level of consciousness, can prevent bronchial aspiration, aspiration pneumonias and respir atory failure 14 . It is important to titrate lactulose dose and enemas appropriately to prevent hypovolaemia that results from diarrhoea and to prevent hypernatraemia (a rise in serum sodium levels) that results from lactulose. Goal stool output in a day should be 3-4 bowel move ments 133 . Lower stool output is insufficient to reduce the intestinal production of ammonia and to increase ammo nia clearance from blood. Higher stool output may induce hypernatraemic dehydration. Patients with grade III-IV encephalopathy should be intubated, as they have a high risk of experiencing bronchial aspiration (of saliva or gastric fluid). Intracranial pressure monitoring and the use of mannitol is not recommended in these patients as cerebral oedema and intracranial hypertension are excep tional in patients with hepatic encephalopathy associated with ACLF
.
Coagulopathy. Coagulopathy in patients with ACLF is often difficult to manage in the setting of fluctuations between a prothrombotic and an ineffective haemostatic state 134, 135 . In the setting of active bleeding and severe coagulopathy, transfusion of platelets, cryoprecipitate (a frozen blood product prepared from plasma used to increase fibrinogen levels) and blood should be consid ered. However, patients should not be prophylactically transfused with plasma for an increased international normalized ratio. Patients with portal vein thrombosis may require anticoagulant therapy to prevent recurrent variceal bleeding.
Intensive care and liver support devices
Admission to critical care units is mandatory in cases of vascular, respiratory or brain failure and is recommended in those with renal failure. Patients with liver and coagu lation failure can still be treated in regular wards, but require strict clinical monitoring. In the CANONIC study 8 , 50% of the patients with ACLF were admit ted to the intensive care unit (86% of those with ACLF grade 3). Owing to the high mortality rate in patients with ACLF, treatments that are able to bridge the time between admission of patients with severe disease (ACLF grade 2 or grade 3 at 3-7 days following admission) to liver transplantation are clearly needed. Extracorporeal liver support systems are potential treatments for ACLF 136, 137 . Bioartificial liver support sys tems use hollowfibre bioreactors containing hepatic cells to support the metabolic and synthetic function of the diseased liver. Currently, only tumour hepatocyte or por cine hepatocyte lines (the Vital Therapies ELAD and the Alliqua HepatAssist 2000 systems) are avail able. A recent randomized trial comparing ELAD versus standard medical treatment did not find any significant effect on survival 136 . Nonbiological systems consist of albu min dialysis techniques and are based on the cap acity of this molecule to remove waterinsoluble substances and proinflammatory molecules (such as PAMPs and ROS) retained in plasma as a consequence of liver failure and systemic inflammation 105 . Moreover, the physiology of albumin function is markedly impaired in patients with decompensated cirrhosis because of severe oxidation of the molecule by endogenous ROS, alter ations in its molecular structure and saturation of other binding sites by waterinsoluble substances produced and/or retained as a consequence of liver failure (such as bilirubin, bile salts and drugs). Three different albumin dialysis systems are currently available: the Gambro molecular adsorbent and recirculating system (MARS), the Prometheus fraction ated plasma separation and absorption (FPSA) system and the Fresenius Medical Care singlepass albumin dialysis (SPAD). MARS, the system that is most extensively evaluated in ACLF, improves systemic haemo dynamics and severe hepatic encephalopathy 136, 137 . However, two large randomized, multicentre studies failed to show an improvement in survival using MARS and FPSA 138, 139 . Finally, an artificial liver device (the University College LondonLiver Dialysis Device) that aims to remove and replace the dysfunctional albumin of patients with cirrhosis and to reduce circulating endo toxaemia is currently under evalu ation 140 . Plasma exchange, a detoxification system that increases survival in patients with acute liver failure 141 , improves hepatic encephalo pathy and liver function in nonrandomized studies in patients with ACLF.
Liver transplantation
Liver transplantation represents the only definitive therapeutic option for patients with ACLF. However, very few studies have assessed its feasibility, selection criteria (indications and contraindications), timing and efficacy 96, [142] [143] [144] [145] [146] [147] [148] . In contrast to patients with acute liver failure, patients with ACLF cannot currently be included in the highurgency transplantation list. Moreover, as the clinical course of ACLF evolves rapidly, the time frame for evaluation and listing is frequently very short. Advanced age, active alcoholism, uncontrolled infec tions and multiple organ failure are the main reasons for contra indication to transplantation or delisting. There is general agreement in considering that tran splantation must be avoided in patients with severe circulatory or respiratory failure and ongoing sepsis. By contrast, for the majority of experienced centres, organ support (renal replacement therapy and mechanical ventilation) does not contra indicate transplantation in ACLF. Current data indicate that less than half of patients with ACLF are listed and that the procedure is feasible in only 10-25% of patients, as >50-70% of the listed patients die on the wait ing list 147 . A recent study in the United States showed that patients with cirrhosis, ACLF and a high MELD score (>40) have higher waitinglist mortality (almost twofold ACLF, acute-on-chronic liver failure; NS, not significant. *P value compares (Chi-square test) the prevalence of potential precipitating events between patients with and without ACLF at enrolment in the CANONIC study. Bacterial infection and active alcoholism were significantly more frequent in patients with ACLF than in those without ACLF, suggesting that they were associated with the development of the syndrome. This was not the case for gastrointestinal bleeding. ‡ Within 3 months prior to inclusion. § Other precipitating events include large volume paracentesis without intravenous administration of albumin (to prevent post-paracentesis circulatory dysfunction), transjugular intrahepatic portosystemic shunt (which is used to treat portal hypertension), major surgery, acute hepatitis (caused by viral infection, ischaemia or drug-induced liver injury) and acute alcoholic hepatitis. Liver biopsy was required for the diagnosis of acute alcoholic hepatitis in the CANONIC protocol, but many patients with active alcoholism had a clinical picture suggestive of this diagnosis. higher) than status 1A candidates (that is, patients with acute liver failure) 145 . Defining criteria to select and priori tize patients with ACLF on the waiting list will help to improve outcomes by providing timely liver transplantation. Several studies show that both living donor liver transplantation and deceased donor trans plantation offer similar results in this setting [146] [147] [148] . The reported outcome of patients transplanted for ACLF is good (FIG. 6) , ranging between 74% and 90% at 5 years, a number similar to that observed in patients transplanted for other indications 96, [144] [145] [146] [147] [148] .
Management algorithm
The three new scoring systems derived from the CANONIC study -the CLIFC OF score (or CLIFSOFA score), the CLIFC ACLF score and the CLIFC AD score -can be used to riskstratify patients with cirrho sis and acute decompensation, to indicate early liver trans plantation and to assess intensive care unit treatment futility 20, 98 (FIG. 7) . The prognosis in ACLF depends not only on the number of organ failures or the CLIFC ACLF score at diagnosis but also on the early response to treatment 96 . As nearly 20% of patients with ACLF grade 3 improve after treatment, patients with three or more organ failures should be admitted to the intensive care unit and should receive unrestricted organ support for a short period of time (3-7 days). The persist ence of three or more organ failures after this intervention may lead to the need to consider a limitation in life sustaining treatments as a fatal outcome is almost invariable in the absence of 'salvage' liver transplantation 19 . A high CLIFC ACLF score (>64 points) after initial interven tion (at 3-7 days) has also been suggested as a potential futility rule in patients without possibilities of early liver transplantation 96 . However, these criteria require further validation. Patients who are potential candidates for early liver transplantation, including living donor liver transplantation, must not be limited in their treatment. In those without options for transplantation, scores and a pragmatic casebycase evaluation should be used for the decision.
Regenerative therapy
A few studies have evaluated the effect of GCSF ther apy in small groups of patients with ACLF 128, 149, 150 . This cytokine mobilizes bone marrowderived stem cells, restores neutrophil function and promotes hepatic regener ation. GCSF administration in nonsevere forms of ACLF reduces the risk of developing organ failure (or failures) and sepsis and improves survival. GCSF ther apy seems to be ineffective in patients with sepsis and in those who have moresevere forms of ACLF. Hepatocyte and stem cell transplantation have also been proposed as potential treatments in ACLF 151 .
Quality of life
Following dismissal from hospital, patients recovering from ACLF may return to functioning in their com munity, receive a liver transplantation, be sent to inter mediate care facilities such as a nursing home or be rehospitalized. The 30day hospital readmission rate is approximately 25% 152 . In the longterm followup of 6 months in the NACSELD study 153 , 27% of patients died, 14% were transplanted and 59% were alive without liver transplantation. After discharge, 45% of patients had subsequent infections. Patients who had repeat infec tions were older and were more likely to use proton pump inhibitors, rifaximin or prophylactic therapy for SBP with norfloxacin 154, 155 . In these last three circumstances, the predisposition to bacterial infections is probably related to gut dysbiosis or colonization by drug multi resistant bacteria. Of crucial importance, patients with infection related ACLF were more likely to be delisted for liver transplantation.
Outlook
ACLF definition
The challenge of obtaining a universal definition of ACLF is an important issue. However, differences between the APASL and western definitions are too important to A proposed management strategy for patients with acute-on-chronic liver failure (ACLF) based on mortality rate data from the CANONIC study 8 . The first step is the assessment of ACLF grade at days 3-7 after initiation of medical management, including organ support. Liver transplantation should be assessed in all patients with ACLF because of high 90-day mortality rates (>20%). Liver transplantation should be performed as early as possible in patients with ACLF grade 2 and grade 3 as they are at considerable risk of short-term (28-day) mortality. In the case of contraindication of liver transplantation, the presence of four or more organ failures (OFs) or a Chronic Liver Failure Consortium (CLIF-C) ACLF score of >64 at days 3-7 after diagnosis could indicate the futility of care. ICU, intensive care unit. Adapted with permission from REF. 96 be solved by consensus agreements alone. These defin itions differ not only in terms of the characteristics of the patients, diagnostic criteria and clinical course but also, and most importantly, in the conceptual view of the disease. The APASL conference definition postulates that the sequence of events in ACLF starts with a hepatic insult that causes acute liver failure and, as a consequence, extrahepatic organ failure (or failures). By contrast, the western definition relies on the concept that the acute impairment in liver function (which, if intense, is defined as liver failure) develops simultaneously to an impair ment in the function of other organs (which, if intense, are also defined as organ failures) as a consequence of intrahepatic or extrahepatic mechanisms. These mech anisms could include intense systemic inflammation related to a massive release of DAMPs from the diseased liver (in the case of acute alcoholic hepatitis, viral hepa titis or DILI) or of PAMPs (by invading bacteria in the case of sepsis or from the intestinal microbiota in patients without clear precipitating events). Such controversy can only be solved by promoting research in this compelling new syndrome.
Clinical challenges
Investigations of ACLF have generally been carried out after the diagnosis of the syndrome. As such, there are few data within the critical period before ACLF development. Prospective observational studies within this period are, therefore, essential, particularly those assessing bio markers or panels of biomarkers of systemic inflam mation that could be of value as predictors of treatment response and survival. Liver pathology in ACLF has also been insufficiently investigated. In patients with cirrho sis due to HBV infection, ACLF occurs in the setting of submassive hepatic necrosis 27 . In patients with alcoholic cirrhosis and active alcoholism, severe alcoholic hepatitis superimposed on cirrhosis is probably the predominant liver histology. Finally, two recent studies have reported severe ductular bilirubinostasis and cholestasis, a lesion that is also seen in patients with sepsis who do not have cirrhosis, as a specific lesion in ACLF 156, 157 .
Insights into pathophysiology
Sequential studies of the innate and adaptive immune system function before and after ACLF are lacking. Such studies are essential to understand the mechanism of ACLF. Moreover, the immune system function might change during the clinical course of the syndrome. As it occurs in sepsis 158 , an initial activation of the immune system in ACLF might be followed by a period of immunosuppression, which would favour further bac terial translocation and progression of organ failure (or failures).
The mechanism of organ or system failure in ACLF is of major interest. Renal failure in cirrhosis is consid ered to be secondary to systemic circulatory dysfunction and impaired renal perfusion. However, recent evidence from studies in sepsis suggest that renal failure might also be a consequence of a direct effect of renal inflam mation, which impairs renal microcirculation and cell function 159 . In fact, there is evidence that inflammation might be involved in the pathogenesis of cardiac dys function, encephalopathy, relative adrenal insufficiency and pulmonary dysfunction in cirrhosis 7 .
A major difficulty for research in ACLF is the lack of appropriate animal models. Carbon tetrachloride induced cirrhosis in rats is an excellent model of cirrhosis, but animals die prior to the development of extrahepatic organ failure 160 . Bile ductligated rats represent an acute model of liver failure and ascites and, in combination with the acute intraperitoneal administration of LPS, have been used as a model of ACLF 161 . However, this model differs markedly from cirrhosis in humans and no extrahepatic organ failure has been documented.
Treatment
The recognition of systemic inflammation as the main mechanism of ACLF opens up new fields in the design of new therapeutic procedures. This knowledge will promote the development of new artificial liver support systems capable of removing not only potentially harm ful molecules retained as a consequence of organ failure but also proinflammatory molecules that cause ACLF. Total plasma exchange 141 is clearly an alternative method to remove PAMPs, DAMPs and free radicals.
However, a major issue in the management of ACLF is prevention. There are three potential effective treat ments that should be explored. The first consists of the prevention of bacterial translocation by longterm oral administration of poorly absorbable antibiotics 107, 110, 162 . Longterm weekly administration of intravenous albu min is the second approach. Preliminary data indicate that this technique prevented bacterial infections, AKI and hepatic encephalopathy and improved survival in a large Italian randomized controlled trial in patients with decompensated cirrhosis 163 . Last, recent investi gations have suggested a central role for defective bile acid receptor (also known as farnesoid Xactivated receptor) signalling in hepatic inflammation and intes tinal bacterial translocation, factors that are known to shape ACLF [164] [165] [166] . Obeticholic acid is a potent bile acid receptor agonist. Recent studies in animals have demonstrated that obeticholic acid lowers portal hyper tension and improves bacterial translocation 165, 166 , sug gesting that it might be of potential benefit in patients with ACLF.
